Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Risankizumab 180 mg vs 90 mg Formulation in Healthy Subjects
NCT05567029Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of risankizumab in Crohn's disease (2 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration up to 113 days, Time to Maximum Observed Plasma Concentration up to 113 days and 5 more. Started Sep 2022; status: completed.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05567029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567029.